|
Sign In to gain access to subscriptions and/or personal tools.
|
Animal Models of Arthritis: Relevance to Human Disease
Alison Bendele
BolderPATH, Inc., University of Colorado. MCD Biology. Boulder, Colorado 80309.
Jennifer Mccomb
BolderPATH, Inc., Boulder, Colorado 80309
TY Gould
BolderPATH, Inc., Boulder, Colorado 80309
Tracy Mcabee
BolderPATH, Inc., Boulder, Colorado 80309
Gina Sennello
BolderPATH, Inc., Boulder, Colorado 80309
Elizabeth Chlipala
BolderPATH, Inc., Boulder, Colorado 80309
Michael Guy
BolderPATH, Inc., Boulder, Colorado 80309
Animal models of arthritis are used to evaluate potential antiarthritis drugs for clinical use. Therefore capacity of the model to predict efficacy in human disease is one of the most important criteria in model selection. Animal models of rheumatoid arthritis (RA) with a proven track record of predictability include rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis, and antigen-induced arthritis in several species. Agents currently in clinical use (or trials) that are active in these models include corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide, interleukin-1 receptor antagonist, and soluble tumor necrosis factor receptors. For some of these agents, the models also predict that toxicities seen at higher doses for prolonged periods would preclude dosing in humans at levels that might provide disease-modifying effects. Animal models of osteoarthritis (OA) include mouse and guinea pig spontaneous OA, meniscectomy and ligament transection in guinea pigs, meniscectomy in rabbits, and meniscectomy and cruciate transection in dogs. None of these models have a proven track record of predictability in human disease because there are no agents that have been proven to provide anything other than symptomatic relief in human OA. Efficacy data and features of the various models of RA and OA are discussed with emphasis on their proven relevence to human disease.
Key Words: Rheumatoid arthritis • osteoarthritis • adjuvant arthritis • type II collagen arthritis • guinea pig • methotrexate • dexamethasone • indomethacin • interleukin 1 receptor antagonist • tumor necrosis factor receptor
References
- Bendele AM (1987). Progressive chronic osteoarthritis in femorotibial joints of partial medial meniscectomized guinea pigs. Vet. Pathol. 24: 444-448.[Abstract]
- Bendele AM, Aitchison R., McAbee T., Sennello G., Frazier J., Chlipala L., and McCabe D. (1998). Sustained blood levels of IL-1ra improve efficacy in animal models of arthritis: Comparison of efficacy in animal models to human clinical data. Arthritis Rheum. (in press).
- Bendele AM, Bendele RA, Hulman JF, and Swann BP (1996). Beneficial effects of diacetylrhein treatment in guinea pigs with spontaneous osteoarthritis. Rev. Pract. Suppl. 6: 35-39.
- Bendele AM and Hulman JF (1988). Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum. 31: 561-565.[Web of Science][Medline]
[Order article via Infotrieve]
- Bendele AM and Hulman JF (1991). Effects of body weight restriction on the development and progression of spontaneous OA in guinea pigs. Arthitis Rheum. 34: 1180-1184.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bendele AM, McComb J., Gould T., Chlipala L., Frazier J., Colagiovanni D., and Edwards C. (1998). Comparative efficacy of sTNF-RI, a novel monomeric recombinant soluble TNF type I receptor, to dimeric sTNF-RI and sTNF-RII IgG1 Fc fusion proteins in animal models of rheumatoid arthritis. Proc. Int. TNF Congr. 7. May, 1998, in Hyannis, Massachusetts.
- Bendele AM and White SL (1987). Early histopathologic and ultrastructural alterations in femorotibial joints of partial medial meniscectomized guinea pigs. Vet. Pathol. 24: 436-443.[Abstract]
- Bendele AM, White SL, and Hulman JF (1989). Osteoarthritis in guinea pigs: Histopathologic and scanning electron microscopic features. Lab. Anim. Sci. 39: 115-1211.
- Bendele AM, White SL, Hulman JF, and Bean JS (1991). Osteoarthritis, model No. 379. In: Handbook: Animal Models of Human Disease, fasc. 18, CC Capen, TC Jones, and G Migaki (eds). Registry of Comparative Pathology, Washington, D.C., pp. 3-6.
- Benslay DN and Bendele AM (1991). Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats. Agents Actions 34: 254-256.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Brackertz D., Mitchell GF, and Mackay IR (1977). Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 20: 841-850.[Web of Science][Medline]
[Order article via Infotrieve]
- Bresnihan B. (1996). Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis. Results of a randomized double blind placebo controlled multicenter trial. Arthritis Rheum. 39: S73 (abstract).[CrossRef]
- Brooks PM and Day RO (1991). Nonsteroidal anti-inflammatory drugs—Differences and similarities. N. Engl. J. Med. 324: 1716-1722.[Web of Science][Medline]
[Order article via Infotrieve]
- Butler RC, Davie Mwj, Worsfold M., and Sharp CA (1991). Bone mineral content in patients with rheumatoid arthritis: Relationship to low-dose steroid therapy. Br. J. Rheumatol. 30: 86-90.[Abstract/Free Full Text]
- Campion GV, Lebsack ME, Lookabaugh J., Gordon J., and Catalano M. (1996). Dose range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1ra arthritis study group. Arthritis Rheum. 88: 1092-1101.
- Carlson RP, Datko LJ, O'Neil-Davis L., Blazek EM, Delustro F., Beideman R., and Lewis AJ (1985). Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats. Int. J. Immunopharmacol. 7: 811-826.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dougados M., Nguyen M., Berdah L., Lequesne M., Mazieres B., and Vignon E. (1994). Evaluation of the chondromodulating effect of diacerhein in hip osteoarthritis. Osteoarthritis Cartilage 2: 19 (B9).
- Drosos AA, Tsifetaki N., Tsiakou EK, Timpanidou M., Tsampoulas C., Tatsis CK, Kotoulas K., and Moutsopoulos HM (1997). Influence of methotrexate on radiographic progression in rheumatoid arthritis: A sixty-month prospective study. Clin. Exp. Rheumatol. 15: 263-267.[Web of Science][Medline]
[Order article via Infotrieve]
- Hunneyball IM, Crossley MJ, and Spowage M. (1986). Pharmacological studies of antigen-induced arthritis in BALB/c mice. I. Characterization of the arthritis and the effects of steroidal and nonsteroidal anti-inflammatory agents. Agents Actions 18: 384-393.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hunneyball IM, Crossley MJ, and Spowage M. (1986). Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line anti-rheumatic drugs and cytotoxic agents on histopathological changes Agents Actions 18: 394-400.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meisel AD and Bullough PG (1984). Osteoarthritis of the knee. In: Atlas of Osteoarthritis, AD Meisel and PG Bullough (eds). Lea and Febiger, Philadelphia, pp. 2.1-2.25, 5.1-5.19.
- Moreland LW, Margolies G., Heck LW, Saway A., Blosch C., Hanna R., and Koopman WJ (1996). Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23: 1845-1848.[Web of Science][Medline]
[Order article via Infotrieve]
- Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettinger RE, Cohen S., Koopman WJ, Mohlen K., Widmer MB, and Blosch CM (1997). Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141-147.[Abstract/Free Full Text]
- Nordling C., Karlsson-Parra A., Jansson L., Holmdahl R., and Klareskog L. (1992). Characterization of a spontaneously occurring arthritis in male DBA/1 mice. Arthritis Rheum. 35: 717-722.[Web of Science][Medline]
[Order article via Infotrieve]
- Pearson CM (1956). Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med. 91: 95-100.[CrossRef][Medline]
[Order article via Infotrieve]
- Seitz M., Loetscher P., Dewald B., Towbin H., Rordorf C., Gallati H., and Gerber NJ (1996). Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1B and IL—8—Markers of remission in rheumatoid arthritis during treatment with methotrexate. J. Rheumatol. 23: 1512-1516.[Web of Science][Medline]
[Order article via Infotrieve]
- Sokoloff L., Crittenden LB, Yamamoto RS, and Jay GE (1962). The genetics of degenerative joint disease in mice. Arthritis Rheum. 5: 531-546.[Medline]
[Order article via Infotrieve]
- Terato K., Hashida R., Miyamoto K., Morimoto T., Kata Y., Kobayashi S., Tajima T., Otake S., Horni H., and Nagai Y. (1982). Histological, immunological, and biochemical studies on type II collagen arthritis in rats. Biomed. Res. 3: 495-523.[Web of Science]
- Trentham DE, Townes AS, and Kang AH (1977). Autoimmunity to type II collagen: An experimental model of arthritis. J. Exp. Med. 146: 857-868.[Abstract/Free Full Text]
- Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, and Staite ND (1993). The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36: 1305-1314.[Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 27, No. 1,
134-142 (1999)
DOI: 10.1177/019262339902700125
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. M. Gillooly, M. A. Pattoli, T. L. Taylor, L. Chen, L. Cheng, K. R. Gregor, G. S. Whitney, V. Susulic, S. H. Watterson, J. Kempson, et al.
Periodic, Partial Inhibition of I{kappa}B Kinase {beta}-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis
J. Pharmacol. Exp. Ther.,
November 1, 2009;
331(2):
349 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Wang
In vivo magnetic resonance imaging of animal models of knee osteoarthritis
Lab Anim,
July 1, 2008;
42(3):
246 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev.,
April 1, 2008;
29(2):
155 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-L. Hsieh
Effects of Ultrasound and Diclofenac Phonophoresis on Inflammatory Pain Relief: Suppression of Inducible Nitric Oxide Synthase in Arthritic Rats
Physical Therapy,
January 1, 2006;
86(1):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Larsson, H. Erlandsson Harris, A. Larsson, B. Mansson, T. Saxne, and L. Klareskog
Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP
Rheumatology,
April 1, 2004;
43(4):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Guzman, M. G. Evans, S. Bove, B. Morenko, and K. Kilgore
Mono-Iodoacetate-Induced Histologic Changes in Subchondral Bone and Articular Cartilage of Rat Femorotibial Joints: An Animal Model of Osteoarthritis
Toxicol Pathol,
October 1, 2003;
31(6):
619 - 624.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D H. Jones, Y-Y Kong, and J M Penninger
Role of RANKL and RANK in bone loss and arthritis
Ann Rheum Dis,
November 1, 2002;
61(90002):
ii32 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
